Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 34.85
- Piotroski Score 2.00
- Grade Neutral
- Symbol (AMAM)
- Company Ambrx Biopharma Inc.
- Price $28.00
- Changes Percentage (0.07%)
- Change $0.02
- Day Low $27.98
- Day High $28.00
- Year High $28.15
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 04/04/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.42
- Trailing P/E Ratio 66.666666666667
- Forward P/E Ratio 66.666666666667
- P/E Growth 66.666666666667
- Net Income $-77,996,000
Income Statement
Quarterly
Annual
Latest News of AMAM
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Cubs beat Dodgers in Yamamoto-Imanaga matchup
The Cubs defeated the Dodgers 6-3 with a five-run eighth inning, including three errors by the Dodgers. Japanese pitchers Yamamoto and Imanaga faced off in a thrilling matchup, leading Chicago to vict...
By CBS News | 2 weeks ago -
Cubs beat Dodgers 6-3 in Yamamoto-Imanaga matchup as LA makes 3 errors in 5-run 8th inning
The Cubs defeated the Dodgers 6-3 after a five-run eighth inning, with errors from the Dodgers aiding the comeback. Japanese pitchers Yamamoto and Imanaga faced off for the first time in MLB, showcasi...
By AP NEWS | 2 weeks ago -
Dodgers Could Get Yoshinobu Yamamoto Back Soon to Bolster Rotation
The Los Angeles Dodgers have managed to stay strong despite injuries, and the return of pitcher Yoshinobu Yamamoto could boost their World Series aspirations. His potential comeback after a shoulder i...
By Newsweek | 1 month ago
